Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced that management will present and host one-on-one meetings at Guggenheim’s 3rd Annual Healthcare Innovation Conference in Boston on Nov. 10, 2026. President and CEO Seth Lederman, M.D., will deliver the company presentation from 4 to 4:25 p.m. ET. A live webcast and replay will be available under the News & Events tab in the Investors section of the company’s website.
The presentation matters because Tonix has recently crossed a significant threshold: it is no longer solely a development-stage story. Its flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), was recently approved as the first new treatment for fibromyalgia in more than 15 years. That approval gives the company a commercial product in an area of high unmet need and anchors a CNS commercial infrastructure that also supports its acute migraine products, Zembrace SymTouch and Tosymra.
Tonix is also working to expand TONMYA’s label. The company is maximizing the science behind the drug in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Beyond TONMYA, the CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is additionally advancing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company notes that its product development candidates are investigational new drugs or biologics whose efficacy and safety have not been established and have not been approved for any indication.
For investors, the Guggenheim conference offers a direct forum to assess how Tonix intends to convert its first approval into a broader commercial and clinical franchise. The full press release is available at https://ibn.fm/f7udM, and the latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP.
The announcement was distributed through InvestorWire, a specialized communications platform focused on wire-grade press release syndication. InvestorWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides services including editorial syndication to 5,000+ outlets and social media distribution. Terms of use and disclaimers applicable to the content are available at https://www.InvestorWire.com/Disclaimer.
